Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Maravai LifeSciences (MRVI) stock

Learn how to easily invest in Maravai LifeSciences stock.

Maravai LifeSciences is planning an initial public offering (IPO) to raise up to $1.35 billion. The company is most well known for its mRNA and RNA products, which are used in vaccine development. Most notably, its CleanCap approach is being used in several vaccine trials for COVID-19, though it's too soon to tell if any of those particular vaccines will make it to market.

Here's what we know so far about the IPO, including how to buy in when the stock goes public.

How to buy shares in Maravai LifeSciences

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MRVI – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Maravai LifeSciences stock price (NASDAQ: MRVI)

Use our graph to track the performance of MRVI stocks over time.

Maravai LifeSciences shares at a glance

Information last updated 2021-07-23.
Latest market close$37.54
52-week range$23.62 - $45.79
50-day moving average $41.36
200-day moving average $36.26
Wall St. target price$50.11
PE ratio 58.8999
Dividend yield N/A (0%)
Earnings per share (TTM) $0.71

Buy Maravai LifeSciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
$0 per year
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Maravai LifeSciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Maravai LifeSciences price performance over time

Historical closes compared with the close of $37.54 from 2021-05-28

1 week (2021-07-16) N/A
1 month (2021-06-25) -12.08%
3 months (2021-04-27) -1.11%
6 months (2021-01-23) N/A
1 year (2020-07-23) N/A
2 years (2019-07-23) N/A
3 years (2018-07-23) N/A
5 years (2016-07-23) N/A

Is Maravai LifeSciences under- or over-valued?

Valuing Maravai LifeSciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Maravai LifeSciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Maravai LifeSciences's P/E ratio

Maravai LifeSciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 59x. In other words, Maravai LifeSciences shares trade at around 59x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

However, Maravai LifeSciences's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.

Maravai LifeSciences's EBITDA

Maravai LifeSciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $206 million.

The EBITDA is a measure of a Maravai LifeSciences's overall financial performance and is widely used to measure a its profitability.

To put Maravai LifeSciences's EBITDA into context you can compare it against that of similar companies.

Maravai LifeSciences financials

Revenue TTM $381.3 million
Operating margin TTM 47.31%
Gross profit TTM $204.4 million
Return on assets TTM 7.02%
Return on equity TTM 52.65%
Profit margin 23.3%
Book value $1.17
Market capitalisation $10.8 billion

TTM: trailing 12 months

Shorting Maravai LifeSciences shares

There are currently 4.9 million Maravai LifeSciences shares held short by investors – that's known as Maravai LifeSciences's "short interest". This figure is 1.2% down from 4.9 million last month.

There are a few different ways that this level of interest in shorting Maravai LifeSciences shares can be evaluated.

Maravai LifeSciences's "short interest ratio" (SIR)

Maravai LifeSciences's "short interest ratio" (SIR) is the quantity of Maravai LifeSciences shares currently shorted divided by the average quantity of Maravai LifeSciences shares traded daily (recently around 1.3 million). Maravai LifeSciences's SIR currently stands at 3.62. In other words for every 100,000 Maravai LifeSciences shares traded daily on the market, roughly 3620 shares are currently held short.

To gain some more context, you can compare Maravai LifeSciences's short interest ratio against those of similar companies.

However Maravai LifeSciences's short interest can also be evaluated against the total number of Maravai LifeSciences shares, or, against the total number of tradable Maravai LifeSciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Maravai LifeSciences's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Maravai LifeSciences shares in existence, roughly 20 shares are currently held short) or 0.0547% of the tradable shares (for every 100,000 tradable Maravai LifeSciences shares, roughly 55 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Maravai LifeSciences.

Find out more about how you can short Maravai LifeSciences stock.

Maravai LifeSciences share dividends

We're not expecting Maravai LifeSciences to pay a dividend over the next 12 months.

You may also wish to consider:

Maravai LifeSciences overview

Maravai LifeSciences Holdings, Inc. , a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in three segments: Nucleic Acid Production, Biologics Safety Testing, and Protein Detection. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services.

Maravai LifeSciences in the news

There are no recent company news

Frequently asked questions

What percentage of Maravai LifeSciences is owned by insiders or institutions?
Currently 0.215% of Maravai LifeSciences shares are held by insiders and 89.85% by institutions.
How many people work for Maravai LifeSciences?
Latest data suggests 460 work at Maravai LifeSciences.
When does the fiscal year end for Maravai LifeSciences?
Maravai LifeSciences's fiscal year ends in December.
Where is Maravai LifeSciences based?
Maravai LifeSciences's address is: 10770 Wateridge Circle, San Diego, CA, United States, 92121

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site